This is not the most recent version of the article. View current version (10 MAR 2014)

Intervention Protocol

Low molecular weight heparin for prevention of central venous catheterization-related thrombosis in children

  1. Prakeshkumar S Shah1,*,
  2. Niketa Shah2

Editorial Group: Cochrane Peripheral Vascular Diseases Group

Published Online: 19 APR 2006

DOI: 10.1002/14651858.CD005982


How to Cite

Shah PS, Shah N. Low molecular weight heparin for prevention of central venous catheterization-related thrombosis in children (Protocol). Cochrane Database of Systematic Reviews 2006, Issue 2. Art. No.: CD005982. DOI: 10.1002/14651858.CD005982.

Author Information

  1. 1

    University of Toronto, Department of Paediatrics and Department of Health Policy, Management and Evaluation, Rm 775A, Toronto, Ontario, Canada

  2. 2

    New Jersey Hospital, Department of Pediatrics, Jersey City, New Jersey, USA

*Prakeshkumar S Shah, Department of Paediatrics and Department of Health Policy, Management and Evaluation, Rm 775A, University of Toronto, 600 University Avenue, Toronto, Ontario, M5G 1XB, Canada. pshah@mtsinai.on.ca.

Publication History

  1. Publication Status: Edited (no change to conclusions)
  2. Published Online: 19 APR 2006

SEARCH

This is not the most recent version of the article. View current version (10 MAR 2014)

 

Abstract

  1. Top of page
  2. Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows:

The primary objective of this review is to determine the prophylactic effect of LMWH on the incidence of CVC-related thrombosis in children.

Secondary objectives are to determine the effect of LMWH on:

(1) occlusion of CVC (defined as inability to infuse fluids through the catheter due to blockage);
(2) number of days of CVC patency;
(3) episodes of catheter-related sepsis (defined as symptoms and signs suggestive of sepsis accompanied by positive blood cultures obtained from a normally sterile site different to a central line, and from the line or catheter tip, each growing the same micro-organism)
(4) abnormality of coagulation profile;
(5) allergic reactions to LMWH;
(6) bleeding complications;
(7) osteoporosis with long-term use;
(8) mortality during therapy.